Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genmab AS

www.genmab.com

Latest From Genmab AS

J&J’s Darzalex Scores Again In Frontline Myeloma

Janssen’s hemato-oncology success rolls on with impressive new overall survival data

Research & Development Blood & Coagulation Disorders

Podcast: Novartis’s $9.7bn Gamble; Higher Drug Prices Post-Brexit? Jefferies Highlights

Join the London-based Eleanor Malone, Andrew McConaghie and Kevin Grogan as they review some of the most eyecatching stories in pharma and healthcare.

Europe Brexit

EU Approvals: J&J's Darzalex Steps Ahead With New Indication

The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.

 

 

ImmunoOncology Approvals

European Biotechs Enter the IPO Big League

2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.

Europe Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Genmab AS
  • Senior Management
  • Jan van de Winkel, PhD, Pres. & CEO
    David A Eatwell, EVP, CFO
    Judith Klimovsky, MD, EVP, Chief Dev. Officer
  • Contact Info
  • Genmab AS
    Phone: (45) 7020 2728
    Kalvebod Brygge 43
    Copenhagen, 1560 V
    Denmark
UsernamePublicRestriction

Register